PATENT CLAIM ANALYSIS

Application Number: 16334229
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-08
Patent Classification: ["514", "263220"]

Abstract:
This disclosure generally relates to dual CLK2/CDK1 inhibitors or more potent and specific CLK inhibitors to target CLK2 and CDK1 kinases in the treatment of germ-line mutations of the spliceosome leading to the development of cancers and other human disease. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claim (Index 3):
The compound of  claim 1 , wherein the compound is selected from:

Metadata:
- Claim Count in Document: 26.0
- Percentile: 99.0
- Lexical Diversity: 1.40816
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16172312', '14650826', '15519109', '16033071', '15892302']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7372662407912739
- 35 USC 102 Novelty (BERT): 0.5011645974800337
- Combined Prediction Score: 0.71365607646015
- Mean Citation Score: 229.402036
- Max Citation Score: 248.27312
- Similarity Product: 199.72660530450813

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test